PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer

Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tum...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Colloids Surf B Biointerfaces
Main Authors: Nagesh, Prashanth K.B., Johnson, Nia R., Boya, Vijaya K.N., Chowdhury, Pallabita, Othman, Shadi F., Khalilzad-Sharghi, Vahid, Hafeez, Bilal B., Ganju, Aditya, Khan, Sheema, Behrman, Stephen W., Zafar, Nadeem, Chauhan, Subhash C., Jaggi, Meena, Yallapu, Murali M.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2016
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5100699/
https://ncbi.nlm.nih.gov/pubmed/27058278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.colsurfb.2016.03.071
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים